A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Overexpression of Human Estrogen Biosynthetic Enzyme Hydroxysteroid (17beta) Dehydrogenase Type 1 Induces Adenomyosis-like Phenotype in Transgenic Mice




TekijätHeinosalo Taija, Rytkönen Kalle T., Saarinen Niina, Järvensivu Päivi, Damdimopoulou Pauliina, Strauss Leena, Orasniemi Satu, Horshauge Petricia, Gabriel Michael, Koskimies Pasi, Ohlsson Claes, Kronqvist Pauliina, Poutanen Matti

KustantajaMDPI

Julkaisuvuosi2022

JournalInternational Journal of Molecular Sciences

Tietokannassa oleva lehden nimiInternational Journal of Molecular Sciences

Artikkelin numero4815

Vuosikerta23

Numero9

DOIhttps://doi.org/10.3390/ijms23094815

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/175140524


Tiivistelmä

Hydroxysteroid (17beta) dehydrogenase type 1 (HSD17B1) is an enzyme that converts estrone to estradiol, while adenomyosis is an estrogen-dependent disease with poorly understood pathophysiology. In the present study, we show that mice universally over-expressing human estrogen biosynthetic enzyme HSD17B1 (HSD17B1TG mice) present with adenomyosis phenotype, characterized by histological and molecular evaluation. The first adenomyotic changes with endometrial glands partially or fully infiltrated into the myometrium appeared at the age of 5.5 months in HSD17B1TG females and became more prominent with increasing age. Preceding the phenotype, increased myometrial smooth muscle actin positivity and increased amount of glandular myofibroblast cells were observed in HSD17B1TG uteri. This was accompanied by transcriptomic upregulation of inflammatory and estrogen signaling pathways. Further, the genes upregulated in the HSD17B1TG uterus were enriched with genes previously observed to be induced in the human adenomyotic uterus, including several genes of the NFKB pathway. A 6-week-long HSD17B1 inhibitor treatment reduced the occurrence of the adenomyotic changes by 5-fold, whereas no effect was observed in the vehicle-treated HSD17B1TG mice, suggesting that estrogen is the main upstream regulator of adenomyosis-induced uterine signaling pathways. HSD17B1 is considered as a promising drug target to inhibit estrogen-dependent growth of endometrial disorders. The present data indicate that HSD17B1 over-expression in TG mice results in adenomyotic changes reversed by HSD17B1 inhibitor treatment and HSD17B1 is, thus, a potential novel drug target for adenomyosis.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 23:24